Inclusion Criteria:

          1. Pathologically (histologically or cytologically) proven diagnosis of prostatic
             adenocarcinoma within 180 days of registration at moderate to high risk for recurrence

          2. History/physical examination (to include at a minimum digital rectal examination of
             the prostate and examination of the skeletal system and abdomen) within 90 days prior
             to registration.

          3. Clinically negative lymph nodes as established by imaging (pelvic ± abdominal CT or
             MRI), (but not by nodal sampling, or dissection) within 90 days prior to registration.

          4. Patients with lymph nodes equivocal or questionable by imaging are eligible if the
             nodes are ≤ 2.0 cm.

          5. No evidence of bone metastases (M0) on bone scan within 90 days prior to registration.

          6. Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative
             for metastasis.

          7. Baseline serum PSA value performed with an FDA-approved assay (e.g., Abbott,
             Hybritech) within 12 weeks (90 days) prior to registration.

          8. Study entry PSA should not be obtained during the following time frames: (1) 10-day
             period following prostate biopsy; (2) following initiation of hormonal therapy; (3)
             within 30 days after discontinuation of finasteride; (4) within 90 days after
             discontinuation of dutasteride.

          9. Zubrod Performance Status 0-2

         10. Complete blood count (CBC)/differential obtained within 2 weeks (14 days) prior to
             registration on study, with adequate bone marrow function

         11. Patient must be able to provide study specific informed consent prior to study entry.

        Exclusion Criteria:

          1. Prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for a
             minimum of 2 years.

          2. Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer

          3. Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy

          4. Previous hormonal therapy

          5. Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset
             of androgen ablation is ≤ 60 days prior to the date of registration.

          6. Use of finasteride within 30 days prior to registration

          7. Use of dutasteride or dutasteride/tamsulosin (Jalyn) within 90 days prior to
             registration

          8. Previous or concurrent cytotoxic chemotherapy for prostate cancer; note that prior
             chemotherapy for a different cancer is allowable. See Section 3.2.1.

          9. Prior radiotherapy, including brachytherapy, to the region of the study cancer that
             would result in overlap of radiation therapy fields

         10. Severe, active co-morbidity including heart issues, infection and liver problems

         11. Patients who are sexually active and not willing/able to use medically acceptable
             forms of contraception

         12. Prior allergic reaction to the hormones involved in this protocol

         13. Patients status-post a negative lymph node dissection are not eligible